Zepbound 12.5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FV412
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,965
Award facts
- Contract value 100% obligated
- $11,964.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,964.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on January 9, 2026, with completion targeted for January 12, 2026. The award is unset-aside and competitively sourced. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the operating subsidiary of parent company Cencora, Inc., which rebranded from AmerisourceBergen in 2023. This delivery order represents a task order under a larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical, which is valued at up to $999,999,999.00 through December 2026 and serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs.
The DLA Troop Support Medical contract vehicle enables AmerisourceBergen to supply a broad spectrum of pharmaceutical products and medical commodities—including brand-name and generic medications, vaccines, and specialty treatments—to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. This delivery order for Zepbound, a FDA-approved diabetes and weight management medication, reflects the company's role in supplying specialty pharmaceuticals across multiple therapeutic domains to military treatment facilities and federal medical institutions. AmerisourceBergen's consistent performance on competitive awards and its significant IDC portfolio demonstrate its capability to meet federal procurement requirements for essential pharmaceutical commodities.
Quick answers
Who was awarded contract SPE2DR26FV412?
SPE2DR26FV412 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 9, 2026.
How much is contract SPE2DR26FV412 worth?
The government has obligated $11,965 on SPE2DR26FV412.
Is contract SPE2DR26FV412 an order under another contract?
Yes. SPE2DR26FV412 is a delivery order under SPE2DR25D1053, an indefinite delivery contract.
Was contract SPE2DR26FV412 competed?
The extent of competition for SPE2DR26FV412 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award